ELVN Latest Press Releases

-- November 5, 2026 --

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update PRNewswire 4:05 PM

-- October 14, 2026 --

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year PRNewswire 4:30 PM

-- October 6, 2026 --

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia PRNewswire 4:06 PM

-- September 3, 2026 --

Enliven Therapeutics to Present at Upcoming Investor Conferences PRNewswire 4:05 PM

-- August 31, 2026 --

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting PRNewswire 6:06 PM

-- August 5, 2026 --

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update PRNewswire 4:05 PM

-- June 15, 2026 --

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares PRNewswire 4:40 PM

-- June 11, 2026 --

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PRNewswire 10:40 PM

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PRNewswire 4:05 PM

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components PRNewswire 8:00 AM

Market Data Delayed 15 Minutes